<<What do you think of CTII as a potential acquisition target in the nearer term?>>
John,
Sorry, but I haven't got a clue.
I do appreciate the long-term potential of CytoTherapeutics. It is a potential blockbuster, but to paraphrase a quotation, "It's the technology, stupid!". I'm willing to take the gamble that the technology proves itself. I may take some profits on the way and do some technical trading from time to time.
Three years ago I was insightful enough to appreciate the potential of biotechnology, but unfortunately not technically astute enough to know which of the biotechs will do well. Also, my timing could've been better.
I've done pretty well on some biotechs because of takeovers, but I've also invested in some bombs. Namely, Xoma and Isis. They may still do well, but I was looking for an early proof-of-concept for both companies and didn't get it.
Genomic companies and companies with drug discovery technologies are hot. I believe these companies have become the biotech version of internet stocks. I own HYSQ and AXPH. Stocks like these and MLNM, AFFX, INCY, HGSI are indeed the future Yahoos.
Stocks like CTII are somewhat riskier. I certainly agree with your points about big pharma's potential acquisition or licensing of stem cell technology, but the technology must continue to prove itself.
Normally, I avoid biotechs that don't have at least one important product in Phase III trials, but CTII is one of my rare exceptions. Genomic related companies are also excepted. In both cases, the potential is just too great to ignore or wait on.
I assume your into other biotechs. What looks good to you?
Regards, Ed |
